title: Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study.
abstract: OBJECTIVE
  Uracil and tegafur in a 4:1 molar concentration ratio (UFT; Bristol-Myers Squibb, Wallingford, CT) has broad anti-tumor activity for cancers arising from the gastrointestinal tract. However, there are no published data regarding the efficacy of leucovorin-modulated UFT in patients with pancreatic cancer. The objective of this trial was to determine the activity and evaluate the toxicity of UFT plus oral calcium leucovorin in patients with advanced pancreatic adenocarcinoma.
  
  
  METHODS
  Fourteen patients with advanced measurable adenocarcinoma of the pancreas were enrolled onto the trial. Patients received 300 mg/m2/d UFT plus 90 mg/d leucovorin administered orally in divided doses every eight hours for 28 days repeated every 35 days. Objective tumor response was evaluated after two courses of therapy.
  
  
  RESULTS
  Fourteen patients were evaluable for response and toxicity. No objective responses were seen. The median (range) time to progression and survival were 14 (1.6-37), and 15 (1.9-62) weeks, respectively. Toxicity was mild with severe (grade 3 or 4) hyperbilirubinemia, pain, diarrhea, transaminitis, venous thrombus, weakness, renal failure, confusion, and edema/ascites seen in three (21%), one (7%), two (14%), one (7%), one (7%), one (7%), one (7%), one (7%), and two (14%) patients, respectively.
  
  
  CONCLUSIONS
  In the 14 patients evaluable, UFT 300 mg/m2/d plus oral leucovorin 90 mg/d administered for 28 days did not demonstrate anti-tumor activity against advanced pancreatic adenocarcinoma; however, this oral regimen was well tolerated and devoid of neutropenia, significant oral mucositis or diarrhea.
authors.affiliation: Section of Hematology/Oncology, University of Chicago Pritzker School of Medicine, IL, USA.
authors.forename: S
authors.initials: S
authors.lastname: Mani
authors.forename: J W
authors.initials: JW
authors.lastname: Kugler
authors.forename: D F
authors.initials: DF
authors.lastname: Sciortino
authors.forename: J C
authors.initials: JC
authors.lastname: Garcia
authors.forename: R H
authors.initials: RH
authors.lastname: Ansari
authors.forename: R
authors.initials: R
authors.lastname: Humerickhouse
authors.forename: F
authors.initials: F
authors.lastname: Michelassi
authors.forename: M C
authors.initials: MC
authors.lastname: Posner
authors.forename: K L
authors.initials: KL
authors.lastname: Shulman
authors.forename: R L
authors.initials: RL
authors.lastname: Schilsky
authors.forename: M
authors.initials: M
authors.lastname: List
authors.forename: E E
authors.initials: EE
authors.lastname: Vokes
authors.forename: S
authors.initials: S
authors.lastname: Benner
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000855:Anorexia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D009325:Nausea / Q000139:chemically induced; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D005641:Tegafur; D014498:Uracil; D002955:Leucovorin